ACB Stock Analysis: Aurora Cannabis | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 167m USD | 12M Return: -41.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.69M
Qual. Beats: -1
Rev. Trend: 87.2%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Aurora Cannabis Inc. (NASDAQ: ACB) is a Canadian-headquartered company that produces, distributes, and sells cannabis products for both medical and consumer (recreational) markets, with operations in Canada and select international markets. The company is classified under the Health Care sector and Pharmaceuticals sub-industry by GICS, reflecting its positioning around pharmaceutical-grade cannabis offerings alongside its broader consumer portfolio.
The companys product range is broad, spanning dried and fresh cannabis, trim, cannabis oils, capsules, edibles, vaporizers, seeds, extracts, concentrates, topicals, and plants. It also offers patient counseling and outreach services, supporting its medical cannabis segment. Aurora sells its products under a portfolio of brands including Aurora, CanniMed, MedReleaf, Pedanios, Whistler, Drift, Greybeard, and others, suggesting a multi-brand strategy aimed at different consumer segments and price points.
Aurora Cannabis was founded in 2013 and is headquartered in Edmonton, Canada. The company trades as a micro-cap stock on NASDAQ with a market capitalization of approximately $176M USD, reflecting a significant decline from its earlier valuations amid broader weakness in the Canadian cannabis sector.
- German medical cannabis exports drive international revenue growth
- Canadian recreational pricing pressure compresses gross margins
- Cost reduction program targets sustained adjusted EBITDA profitability
| Net Income: -75.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.06 > 0.02 and ΔFCF/TA -5.65 > 1.0 |
| NWC/Revenue: 106.6% < 20% (prev 106.4%; Δ 0.17% < -1%) |
| CFO/TA -0.02 > 3% & CFO -13.5m > Net Income -75.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.94 > 1.5 & < 3 |
| Outstanding Shares: last quarter (57.5m) vs 12m ago 3.08% < -2% |
| Gross Margin: 56.64% > 18% (prev 54.65%; Δ 1.99% > 0.5%) |
| Asset Turnover: 42.87% > 50% (prev 40.49%; Δ 2.37% > 0%) |
| Interest Coverage Ratio: -2.80 > 6 (EBIT TTM -29.1m / Interest Expense TTM 10.4m) |
| A: 0.55 (Total Current Assets 398.5m - Total Current Liabilities 67.1m) / Total Assets 602.6m |
| B: -10.72 (Retained Earnings -6.46b / Total Assets 602.6m) |
| C: -0.04 (EBIT TTM -29.1m / Avg Total Assets 725.2m) |
| D: 5.73 (Book Value of Equity 513.2m / Total Liabilities 89.5m) |
| Altman-Z'' = -25.58 = D |
| DSRI: 1.17 (Receivables 44.7m/42.2m, Revenue 310.9m/343.3m) |
| GMI: 0.96 (GM 54.65% / 56.64%) |
| AQI: 1.07 (AQ_t 0.13 / AQ_t-1 0.12) |
| SGI: 0.91 (Revenue 310.9m / 343.3m) |
| TATA: -0.10 (NI -75.0m - CFO -13.5m) / TA 602.6m) |
| Beneish M = -2.96 (Cap -4..+1) = A |
As of July 14, 2026, the stock is trading at USD 2.67 with a total of 1,045,113 shares traded. Over the past week, the price has changed by -1.48%, over one month by -9.49%, over three months by -23.28% and over the past year by -41.70%.
Current recommended Stop Loss: 2.50 (which is 6.4% or 1.4 ATR below the current price).
Aurora Cannabis has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy ACB.
- StrongBuy: 3
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 6.2 | 133.3% |
Market Cap CAD = 237.0m (167.2m USD * 1.4169 USD.CAD)
P/E Forward = 19.1571
P/S = 0.5217
P/B = 0.4596
Revenue TTM = 310.9m CAD
EBIT TTM = -29.1m CAD
EBITDA TTM = -15.7m CAD
Long Term Debt = 18.2m CAD (estimated: total debt 23.9m - short term 5.74m)
Short Term Debt = 5.74m CAD (from shortTermDebt, last quarter)
Debt = 23.9m CAD (from shortLongTermDebtTotal, last quarter) (leases 23.9m already included)
Net Debt = -141.2m CAD (calculated: Debt 23.9m - CCE 165.1m)
Enterprise Value = 95.8m CAD (237.0m + Debt 23.9m - CCE 165.1m)
Interest Coverage Ratio = -2.80 (Ebit TTM -29.1m / Interest Expense TTM 10.4m)
EV/FCF = -2.66x (Enterprise Value 95.8m / FCF TTM -36.1m)
FCF Yield = -37.65% (FCF TTM -36.1m / Enterprise Value 95.8m)
FCF Margin = -11.60% (FCF TTM -36.1m / Revenue TTM 310.9m)
Net Margin = -24.14% (Net Income TTM -75.0m / Revenue TTM 310.9m)
Gross Margin = 56.64% ((Revenue TTM 310.9m - Cost of Revenue TTM 134.8m) / Revenue TTM)
Gross Margin QoQ = 47.68% (prev 49.50%)
Tobins Q-Ratio = 0.16 (Enterprise Value 95.8m / Total Assets 602.6m)
Interest Expense / Debt = 43.46% (Interest Expense 10.4m / Debt 23.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -23.0m (EBIT -29.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.94 (Total Current Assets 398.5m / Total Current Liabilities 67.1m)
Debt / Equity = 0.05 (Debt 23.9m / totalStockholderEquity, last quarter 513.2m)
Debt / EBITDA = 9.01 (negative EBITDA) (Net Debt -141.2m / EBITDA -15.7m)
Debt / FCF = 3.92 (negative FCF - burning cash) (Net Debt -141.2m / FCF TTM -36.1m)
Total Stockholder Equity = 534.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -10.35% (Net Income -75.0m / Total Assets 602.6m)
RoE = -14.05% (Net Income TTM -75.0m / Total Stockholder Equity 534.0m)
RoCE = -5.27% (EBIT -29.1m / Capital Employed (Equity 534.0m + L.T.Debt 18.2m))
RoIC = -4.38% (negative operating profit) (NOPAT -23.0m / Invested Capital 525.7m)
WACC = 11.80% (E(237.0m)/V(260.9m) * Re(9.53%) + D(23.9m)/V(260.9m) * Rd(43.46%) * (1-Tc(0.21)))
Discount Rate = 9.53% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 85.05 | Cagr: 8.92%
[DCF] Fair Price = unknown (Cash Flow -36.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -4.0 | # QB: -1
Revenue Correlation: 87.25 | Revenue CAGR: 12.77% | SUE: -1.42 | # QB: -1
EPS current Quarter (2026-06-30): EPS=-0.20 | Chg30d=-146.88% | Revisions=-25% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.14 | Chg30d=N/A | Revisions=-25% | Analysts=4
EPS current Year (2027-03-31): EPS=-0.32 | Chg30d=-521.73% | Revisions=-57% | GrowthEPS=+84.9% | GrowthRev=-8.6%
EPS next Year (2028-03-31): EPS=0.02 | Chg30d=-92.99% | Revisions=+0% | GrowthEPS=+105.6% | GrowthRev=+8.7%
[Analyst] Revisions Ratio: -55% (up=1, down=7)